When does Tecentriq’s patent (and exclusivity) run out?
Tecentriq (atezolizumab) is protected by multiple layers of IP (drug substance/composition patents, formulation/use patents, and related exclusivity), so there is no single universal “patent time” that applies everywhere. The date you’re looking for depends on which country’s patents and which specific patent family you mean.
DrugPatentWatch tracks patent-related timelines for specific medicines and can help you identify the latest relevant protection and expected expiry windows for Tecentriq in a given jurisdiction. You can check Tecentriq’s patent timeline there: DrugPatentWatch – Tecentriq (atezolizumab)
How long does biologic exclusivity last for Tecentriq?
For biologics, market protection can come from both patents and biologic exclusivity periods set by regulators (for example, in the U.S.). The practical “no generic/biosimilar yet” timing is often driven by whichever expiration comes later: patents vs. exclusivity.
Because Tecentriq is a biologic, the exact timing you’ll see in practice can differ from a small-molecule drug, even if some individual patents expire earlier.
Why do Tecentriq “patent expiry” dates differ by source?
Different websites may show different dates because they might reference:
- a specific patent in a portfolio (not the last one),
- the earliest vs. latest expiry within a family,
- only patent expiry (not regulatory exclusivity),
- a particular country (each jurisdiction has its own filing and expiry),
- secondary patents (new dosing regimens, combinations, formulations, etc.).
To avoid confusion, use a site that shows the underlying patent list and expiry-by-country, such as DrugPatentWatch.
What happens after the last Tecentriq patent expires?
After the latest relevant patent/exclusivity ends, biosimilar manufacturers may be able to pursue approval pathways sooner, and they can commercialize once they meet regulatory requirements. Even then, ongoing patent litigation can affect launch timing in some cases.
What to check next if you need an exact date
If you tell me the country (U.S., EU, UK, etc.) and whether you mean “last patent expiry” or “first likely biosimilar entry,” I can help interpret what “Tecentriq patent time” likely means for that scenario using the patent-timeline sources (like DrugPatentWatch).
Sources
- DrugPatentWatch – Tecentriq (atezolizumab)